


Corporate presentation and growth strategy 2020–23

Safe harbour

This presentation contains forward-looking statements related to our future growth, trends in our operating companies' businesses and industries, and our financial and operational results and performance that are based on current expectations, forecasts and assumptions involving risks and uncertainties that could cause actual outcomes and results to differ materially. In some cases, forward-looking statements can be identified by the use of words such as "outlook," "may," "could," "expect," "intend," "plan," "seek," "anticipate," "believe," "estimate," "predict," "potential," "continue," "likely," "will," "would," "illustrative," or the negative of such words or other comparable words. Specific risks and uncertainties that could cause our actual results to differ materially from those expressed in our forward-looking statements include but are not limited to: variability of operating results among periods, which include the pace, size and nature of acquisitions, investments, dispositions and other realization events and activities within the pharmaceutical and pharmacy industries.

These and other risks and uncertainties and factors are discussed in the Company's various public filings at www.sedar.com or on the Company's website, www.groupekda.ca. These risks, uncertainties and factors may cause our actual financial and operational results and performance to differ materially from the expectations expressed or implied by the forward-looking statements contained in this presentation. Any forward-looking statement speaks only as of the date on which it is made. We do not undertake to update any forward-looking statement, except as required by applicable law.

The last four years saw gross sales increase through a combination of organic growth and M&A



\$23 million
in gross sales

50
employees

750
health professional
contractors

1,100
clients

Pharmacy staff placement and logistics



In a context of talent scarcity, Alliance Pharma has gained prominence in the field of **staff placement and continuing education programs**. Services are provided within personalized frameworks that promote stringent ethical standards.

Current services

- Replacement pharmacists and technical assistants
- Human resource management and scheduling

Growing business in new fields

- Replacement dentists and dental hygienists



Logistik Pharma specializes in pharmacy re-engineering through optimized work organization and comprehensive patient care.

DCCV

- Dispills
- Workflow
- Automated filling devices

Workflow

- Operation optimization
- Workflow fluidity
- Error reduction

Ongoing education

- Online and in-class training for pharmacists and pharmacy technical assistants, human resources and crisis management consulting services
- Conferences and webinars
- INR-level management
- Patient management and the role of technical assistants
- Organizational diagnosis and management

Education services to doctors and training



Superior medical education and communications

From educational strategy development to execution, LIV provides clinical evidence to health professionals and manages educational programs in a diverse number of therapeutic areas.

**+Growing focus on
Oncology**



Cardiology &
Internal
Medicine



Nephrology



Endocrinology
& Diabetes



Neuroscience



Gastroenterology



Oncology &
Hematology



Respiratory



Dermatology



Rare Disease



Rheumatology



Infectious
Disease




Anesthesiology

A stethoscope is positioned diagonally across the top of a tablet. The tablet screen shows the letters 'CBD' in a large, light blue font. Below the text, a faint chemical structure of a cannabinoid molecule is visible, featuring a six-membered ring with a hydroxyl group (-OH) and a double bond. The background of the tablet has a grid pattern.

CBD

As healthcare professionals are now trying to catch up and adjust to demand regarding therapeutic cannabis, we've captured new opportunities.

**Bringing together
our core businesses
with software and
cloud technology
to create:**




**The world's first
patient-centric
health ecosystem
addressing THC/CBD
interactions**

ELIXIR  420


Elixir 420 is an awaited innovation

- **To link international opinion leaders to the medical community**
- **To inform doctors on how to prescribe medical cannabis**
- **To inform medical professionals about the latest development on therapeutic uses of cannabis**



A total of **337** drugs
are known to interact
with cannabis.


**There's a lack
of clear guidance
holding back Canadian
physicians from
prescribing medical
cannabis to
their patients.**




Patients are presently left
to choose therapeutic cannabis
products on their own.

Source: Health Canada 2019

**ELIXIR 420 brings together
skill sets and connected
technologies that
will help medical
prescriptions stay safe.**



Elixir 420 Health ecosystem




Elixir 420

Immersive medical education and training platform

The Elixir 420 platform will connect international opinion leaders and specialists to the medical community to inform them on how to prescribe medical cannabis.

It will feature the latest development on therapeutic use of cannabis.




Elixir 420

Simple connectivity

Elixir 420 connects seamlessly to existing EMRs.

Physicians have little time to work with complex IT applications, and require simple, quick and efficient solutions. They will transact mostly if not exclusively through a platform that gathers their most important sources.






New cultures and structures are needed in patient care as prescription interactions with cumulative THC/CBD concentrations may cause serious health risks their patients.

kDa is in a first mover's position

We'll be ready to expand to Europe in 2021

With a population of more than 742 million, the European Union **is the largest regional economy in the world**, with a GDP that's 11 times the size of Canada's.

It's expected to become **the largest medical cannabis market.**



Our senior management team have demonstrated insightful knowledge



Marc Lemieux
President &
Chairman of the Board
B.Admin

15 years in the pharmaceutical industry:

President, Co-Founder, AlliancePharma

Led the company to become a leader in pharmacy staffing in Quebec. In 2015 AlliancePharma went public and has since become part of the KDA Group (TSX-V .KDA).

President, Founder, AllianceMédicale

A medical distribution company for the hospital environment that promotes orthopedic and spinal surgery products from Zimmer, Conmed Linvatec and several other European companies.

Sales and marketing professional, Abbott Laboratory, GlaxoSmithkline, Wyeth-Ayerst



Sylvain Duvernay
Chief Executive Officer
B.Admin., C.International Trade

20 years of experience in international businesses:

CEO, Capcium Inc.

Led Capcium to become the key softgel supplier for the pharmaceutical, nutritional and medicinal cannabis industries.

Vice President & GM Pharmascience

Responsible of the injectable business unit and US market

President & CEO, Uman Pharma Inc.

Led the acquisition of the Bristol-Myers Squibb facility in Candiac where he developed a business model for the injectable business. The company was sold to Pharmascience in November 2014.

Senior Vice President, Strides Arcolab Ltd.

Canadian operations and U.S development of pharmaceutical generic products: softgels, injectables and solid doses.



Pierre Monet
Chief Financial Officer
CPA, ASC

35 years of involvement in several financings, acquisitions, divestitures and restructurings:

VP Finance & CFO, Terranueva Corporation

Licensed cannabis producer, Canada

VP Finance & CFO, Pershimco Resources

Gold mining, Panama

VP Finance & CFO, Dynacor Gold Mines

Gold mining, Peru

VP Finance, Administration & Treasurer , Iron Ore Company (IOC),

Iron ore mining, Canada

VP Finance. Avestor LLC,

High technology lithium batteries, Canada

VP Finance at Alliance Forest Products

Pulp and paper, U.S.

President, Malaga inc.,

Tungsten mining company, Peru



Jean Pierre Robert
Chief Operating Officer
Bsc Chemistry, MBA

President CTS Sante

An accelerator offering a unique value proposition. For start-ups with professional framework that allows them to reach the market and to receive international visibility

CEO Cadens Medical imaging (now Imagia Cybernetics)


A start-up specialized in the development of advanced artificial intelligence to discover medical breakthroughs

COO Draxis Specialty Pharmaceuticals Inc. (Nasdaq/TSX)

A specialized manufacturer of high added value sterile products for the pharmaceutical industry.


Ownership and accountability have enabled timely decision making

Capitalization table	# of shares in millions	% of shares
Company executives, management	58,77	49,63
Shares in circulation	39,64	33,48
Partner-TENSHI	20,00	16,89
Total shares	118,42	100,00



It's time to partner up

We need to keep our go-to practitioners informed and smart about THC/CBD posology and interactions.



Thank you